Gold-Enhanced Brachytherapy by a Nanoparticle-Releasing Hydrogel and 3D-Printed Subcutaneous Radioactive Implant Approach.

Adv Healthc Mater

Département de Génie des Mines, de la Métallurgie et des Matériaux, Centre de Recherche sur les Matériaux Avancés (CERMA), Université Laval, Québec, G1V 0A6, Canada.

Published: September 2023

Brachytherapy (BT) is a widely used clinical procedure for localized cervical cancer treatment. In addition, gold nanoparticles (AuNPs) have been demonstrated as powerful radiosensitizers in BT procedures. Prior to irradiation by a BT device, their delivery to tumors can enhance the radiation effect by generating low-energy photons and electrons, leading to reactive oxygen species (ROS) production, lethal to cells. No efficient delivery system has been proposed until now for AuNP topical delivery to localized cervical cancer in the context of BT. This article reports an original approach developed to accelerate the preclinical studies of AuNP-enhanced BT procedures. First, an AuNP-containing hydrogel (Pluronic F127, alginate) is developed and tested in mice for degradation, AuNP release, and biocompatibility. Then, custom-made 3D-printed radioactive BT inserts covered with a AuNP-containing hydrogel cushion are designed and administered by surgery in mice (HeLa xenografts), which allows for measuring AuNP penetration in tumors (≈100 µm), co-registered with the presence of ROS produced through the interactions of radiation and AuNPs. Biocompatible AuNPs-releasing hydrogels could be used in the treatment of cervical cancer prior to BT, with impact on  the total amount of radiation needed per BT treatment, which will result in benefits to the preservation of healthy tissues surrounding cancer.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11469283PMC
http://dx.doi.org/10.1002/adhm.202300305DOI Listing

Publication Analysis

Top Keywords

cervical cancer
12
localized cervical
8
aunp-containing hydrogel
8
gold-enhanced brachytherapy
4
brachytherapy nanoparticle-releasing
4
nanoparticle-releasing hydrogel
4
hydrogel 3d-printed
4
3d-printed subcutaneous
4
subcutaneous radioactive
4
radioactive implant
4

Similar Publications

Rare cancer survivorship research funding at the National Institutes of Health (NIH), 2017 to 2023.

Cancer Causes Control

January 2025

Office of Cancer Survivorship, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.

Purpose: Rare cancers are defined as those for which there are less than 15 cases per 100,000 in the population annually. While much progress in detection and treatment has been made over the past decade for many rare cancers, less progress has been made in understanding survivorship needs. The objective of this study was to characterize the National Institutes of Health (NIH) cancer survivorship grant portfolio focused on rare cancers and to identify gaps specific to this area of science.

View Article and Find Full Text PDF

Background: Cisgender women living with HIV (WLWH) are disproportionately impacted by cervical cancer. Nevertheless, disparities in uptake and implementation of cervical cancer services persist in sub-Saharan Africa, where population-level estimates of screening coverage remain scarce.

Methods: We pooled data from nationally representative Population-based HIV Impact Assessment (PHIA) surveys conducted in Ethiopia, Malawi, Rwanda, Tanzania, Zambia, and Zimbabwe (2015-2019).

View Article and Find Full Text PDF

Cancer is a major global concern. Despite considerable advancements in cancer therapy and control, there are still large gaps and requirements for development. In recent years, various naturally occurring anticancer drugs have been derived from natural resources, such as alkaloids, glycosides, terpenes, terpenoids, flavones, and polyphenols.

View Article and Find Full Text PDF

Clear cell adenocarcinoma of the cervix (CCAC) is a rare subtype of cervical adenocarcinoma. It has been linked to intrauterine exposure to diethylstilbestrol (DES) but can happen in non-DES-exposed patients, albeit less commonly. Presentation is largely vaginal bleeding, emphasizing the importance of considering CCAC in the differential of abnormal vaginal bleeding despite the tumor's rarity.

View Article and Find Full Text PDF

Introduction Human papillomavirus (HPV) is a well-documented cause of cervical cancer, leading to significant mortality that may be decreased through screening and the administration of HPV vaccination. Our understanding of New Zealand immigrants' knowledge, attitudes, and perceptions of the HPV vaccine is limited. Preliminary research shows that immigrants have low knowledge and negative perceptions of the HPV vaccine and that cervical cancer and HPV awareness was low among African parents.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!